Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

6.2K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.2K
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

722
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
722
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

853
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
853

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A bounded hazard ratio Cox model for the effect of time to treatment on mortality.

Statistical methods in medical research·2026
Same author

Reply: A Call for High-Level Evidence Before Routine Implementation of Posttreatment SPECT.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

A Scoping Review of the Challenges and Future Perspectives in the Use of Alpha-Emitters for Metastatic Ovarian Cancer.

Molecules (Basel, Switzerland)·2026
Same author

MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial.

Nature communications·2026
Same author

Ethiodized oil interference of planned radioiodine therapy post thoracic duct embolization: report of 2 cases.

JCEM case reports·2026
Same author

An international study of factors affecting variability of dosimetry calculations, part 5: impact of segmentation methods.

EJNMMI physics·2026
Same journal

Posttreatment ⁶⁸Ga-FAP-2286 PET/CT Parameters for Response and Survival Assessment After ¹⁷⁷Lu-FAP-2286 Radioligand Therapy in Advanced Solid Tumors.

Clinical nuclear medicine·2026
Same journal

18F-FDG PET/CT Imaging of Multiple Inflammatory Myofibroblastic Tumors.

Clinical nuclear medicine·2026
Same journal

Intense Incidental F-18 DOPA Uptake in Low-grade Prostate Adenocarcinoma: A Potential Diagnostic Pitfall.

Clinical nuclear medicine·2026
Same journal

A Prospective Head-to-Head Comparison of HER2-Targeted and 18F-FDG PET/CT for Detecting Axillary Lymph Node Metastases Among Newly Diagnosed HER2-Positive and HER2-Low Breast Cancer.

Clinical nuclear medicine·2026
Same journal

Epileptogenic Brain Metastasis Early Positive on 18FDG PET/CT Compared to MRI.

Clinical nuclear medicine·2026
Same journal

Dural Manifestation of Langerhans Cell Histiocytosis​: Multimodality Imaging Approach.

Clinical nuclear medicine·2026
See all related articles

Related Experiment Video

Updated: May 1, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

9.1K

Assessing PSMA Receptor Availability Using 68Ga-PSMA-11 PET/CT Following 177Lu-PSMA-617 Therapy Administration.

Molly E Roseland1, Kellen J Fitzpatrick1, Zhonglin Lu1

  • 1Departments of Radiology.

Clinical Nuclear Medicine
|March 2, 2026
PubMed
Summary
This summary is machine-generated.

177Lu-PSMA-617 treatment for prostate cancer causes temporary decreases in PSMA protein binding. Tumor uptake of the drug reduces significantly early after treatment but recovers over time.

Keywords:
PSMA PETprostate cancerradioligand therapyreceptor saturation

More Related Videos

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.8K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.3K

Related Experiment Videos

Last Updated: May 1, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

9.1K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.8K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.3K

Area of Science:

  • Nuclear medicine
  • Radiopharmaceutical therapy
  • Prostate cancer research

Background:

  • Prostate-specific membrane antigen (PSMA) targeted radioligand therapy, such as with 177Lu-PSMA-617, is a key treatment for metastatic castrate-resistant prostate cancer.
  • The efficacy of 177Lu-PSMA-617 relies on its binding to PSMA receptors on cancer cells.
  • Potential saturation of PSMA receptors by the therapeutic radioligand could impact subsequent drug uptake and treatment effectiveness.

Purpose of the Study:

  • To investigate the pharmacological effect of a standard 7.4 GBq dose of 177Lu-PSMA-617 on PSMA protein expression.
  • To quantify changes in 68Ga-PSMA-11 uptake using PET imaging following 177Lu-PSMA-617 therapy.
  • To assess the time course of PSMA receptor saturation and recovery after therapy.

Main Methods:

  • Six patients with metastatic castrate-resistant prostate cancer underwent 68Ga-PSMA-11 PET/CT scans.
  • Imaging was performed at multiple time points: baseline, early (0.5-2 hours), and late (~3 days) after the first cycle of 177Lu-PSMA-617 therapy.
  • Standardized uptake values (SUVmean) in tumors and organs were compared between baseline and post-therapy scans.

Main Results:

  • A significant average decrease of 45% in tumor SUVmean was observed in patients scanned early after therapy (P<0.001).
  • Early post-therapy imaging also revealed substantial reductions in SUVmean in kidneys, parotid glands, and liver.
  • In contrast, late post-therapy scans showed only minor, persistent declines in tumor SUVmean (average -9%, P=0.42), indicating receptor recovery.

Conclusions:

  • Administration of 177Lu-PSMA-617 leads to measurable, temporary decreases in PSMA binding, with recovery observed over approximately three days.
  • Increasing therapeutic dosage per cycle may not proportionally enhance tumor uptake due to receptor saturation dynamics.
  • Further research with larger cohorts, standardized imaging protocols, and pharmacokinetic modeling is recommended to validate these findings.